Key facts
- This page summarizes Mark Corrigan's Form 4 filing for Wave Life Sciences Ltd. (WVE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Aug 2024, 18:00.
Mark Corrigan - 12 Aug 2024 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)
- Reporting relationship
- Director
- Issuer ticker
- WVE
- Reported as of
- 12 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2024, 18:00:06 UTC
- Prior SEC filing
- 14 Jun 2024
- Next SEC filing
- 13 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Corrigan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Corrigan filed Form 4 for Wave Life Sciences Ltd. (WVE) on 14 Aug 2024.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WVE
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +32,230
- Change %
- Price
- $0.000000
- Shares after
- 32,230
- Date
- 12 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WVE
transaction
Derivative
Share Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +64,460
- Change %
- Price
- $0.000000
- Shares after
- 64,460
- Date
- 12 Aug 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 64,460
- Exercise price
- $5.37
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2025 annual general meeting or August 12, 2025; and (ii) the earlier of the Company's 2026 annual general meeting or August 12, 2026.
Footnote F2
The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 12, 2024, through the two-year period following the grant date.